New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Significant Increase in Major Bleeding in Patients with Venous Thromboembolism

NEWS RELEASE New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Signicant Increase in Major Bleeding in Patients with Venous Thromboembolism 3/18/2017 1

The release as fetched from its publisher. jnj.com ↗